Adverse effects of antiepileptic drugs (Q55899120)

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Tolerability of antiseizure medications: implications for health outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Clinical and Economic Impact of Adverse Drug Reactions in Hospitalized Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Adverse drug reactions: definitions, diagnosis, and management

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Commission on Outcome Measurement in Epilepsy, 1994-1997: final report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Strategies to detect adverse effects of antiepileptic drugs in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Adverse reactions to antiepileptic drugs: a multicenter survey of clinical practice. Collaborative Group for Epidemiology of Epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Quality of life of people with epilepsy: a European study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Parent-completed scales for measuring seizure severity and severity of side-effects of antiepileptic drugs in childhood epilepsy: development and psychometric analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

A method of quantification for the evaluation of antiepileptic drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

The Neurotoxicity Scale: the validity of a patient-based scale, assessing neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

The Portland Neurotoxicity Scale: validation of a brief self-report measure of antiepileptic-drug-related neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

What is the role of depressive symptoms among other predictors of quality of life in people with well-controlled epilepsy on monotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Determinants of quality of life in people with epilepsy and their gender differences

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Are adverse effects of antiepileptic drugs different in symptomatic partial and idiopathic generalized epilepsies? The Portuguese–Brazilian validation of the Liverpool Adverse Events Profile

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Validation of the Chinese version of the Liverpool Adverse Events Profile in patients with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Overtreatment in epilepsy: how it occurs and how it can be avoided

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Adverse antiepileptic drug effects in new-onset seizures: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Adverse effects of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

CNS adverse events associated with antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Novel medications for epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Neuropsychological effects of epilepsy and antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Neuropsychological and behavioral effects of antiepilepsy drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Effects of antiepileptic drugs on mood and behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Topiramate and psychiatric adverse events in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Psychiatric adverse events during levetiracetam therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Genetic basis for idiosyncratic reactions to antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Idiosyncratic adverse reactions to antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Serum anticonvulsant concentrations and the risk of drug induced skin eruptions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Medical genetics: a marker for Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Evaluation of case reports of aplastic anemia among patients treated with felbamate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Felbamate: consensus of current clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Risk of aplastic anemia in patients using antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Population-based drug-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Idiosyncratic drug-induced agranulocytosis or acute neutropenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Liver transplantation for acute liver failure from drug induced liver injury in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Hepatotoxicity associated with antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Valproic acid-induced pancreatitis: 16 new cases and a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Adverse effects of antiepileptic drugs: a brief overview of important issues

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Bodyweight gain and anticonvulsants: a comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Metabolic consequences of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Treatment of Epilepsy to Optimize Bone Health

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Understanding and interpreting vision safety issues with vigabatrin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Vigabatrin and epilepsy: lessons learned

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcom

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Comparative safety of antiepileptic drugs during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Early cognitive development in children born to women with epilepsy: a prospective report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Antiepileptic drugs and neurodevelopment: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Cancer risk in people with epilepsy: the role of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Phenytoin-induced pseudolymphoma: reevaluation using modern molecular biology techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Clinically relevant drug interactions with antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Adding valproate to lamotrigine: a study of their pharmacokinetic interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Interactions between antiepileptic drugs and hormonal contraception

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Oxcarbazepine: pharmacokinetic interactions and their clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Lamotrigine-associated rash: risk/benefit considerations in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Perceived Impact of Childhood-onset Epilepsy on Quality of Life as an Adult

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Optimizing health outcomes in active epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Adjustment of treatment increases quality of life in patients with epilepsy: a randomized controlled pragmatic trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Safety review of adult clinical trial experience with lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Predictors of Lamotrigine-associated rash

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021

Lamotrigine and aseptic meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970153-9

7 January 2021